First Manhattan’s Larimar Therapeutics LRMR Stock Holding History

First Manhattan’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,000	Closed	-$39K	–	1638
2021 Q2	$39K	Sell	4,000 -7,000	-64%	-$79.1K	﹤0.01%	1035
2021 Q1	$160K	Hold	11,000	–	–	﹤0.01%	746
2020 Q4	$235K	Hold	11,000	–	–	﹤0.01%	641
2020 Q3	$166K	Hold	11,000	–	–	﹤0.01%	684
2020 Q2	$141K	Buy	+11,000	New	+$128K	﹤0.01%	707
2019 Q1	–	Sell	-466	Closed	-$27K	–	1433
2018 Q4	$27K	Buy	+466	New	+$46K	﹤0.01%	1029

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

First Manhattan's LRMR Position: Q3 2021 in Review

First Manhattan sold out of Larimar Therapeutics (LRMR) in Q3 2021, closing a stake of 4,000 shares — an estimated $39K sold.

First Manhattan first reported a position in LRMR in Q4 2018 and held it in 6 quarters. The position peaked at $235K in Q4 2020. 54 funds tracked by Wall St. Rank hold LRMR as of Q3 2021.

First Manhattan reported no remaining Larimar Therapeutics position as of Q3 2021 after selling out during the quarter.
First Manhattan sold 4,000 Larimar Therapeutics shares in Q3 2021, an estimated $39K.
First Manhattan first reported a position in Larimar Therapeutics in Q4 2018 and held it in 6 quarters.
First Manhattan's Larimar Therapeutics position peaked at $235K in Q4 2020.
54 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2021.

Based on First Manhattan's 13F filing for Q3 2021, filed 15 Nov 2021.